Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: concertpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/5/2021 | $13.00 → $9.00 | Buy | Mizuho |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and business development in the biopharmaceutical and biotechnology industries. “We are pleased to welcome Nancy to our Board of Directors. Her experience at a broad range of companies from both a
Mizuho reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $9.00 from $13.00 previously
Truist reiterated coverage of Concert Pharmaceuticals with a rating of and set a new price target of $22.00 from $30.00 previously
Truist Securities reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $30.00 previously
HC Wainwright resumed coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $17.00 from $25.00 previously
15-12G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
SC TO-T/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 14D9/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 14D9 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC TO-T - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC TO-C - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata. In light of the FDA approval of a different JAK inhibitor as the first treatment for alopecia areata, the FDA previously notified Concert that it was reviewing the Breakthrough Therapy designation previously granted for deuruxolitinib. At the FDA's request, Concert submitted additional clinical data an
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale
New Analyses Presented on the Effect of Baseline Severity and Duration of Current Episode of Hair Loss on Scalp Hair Regrowth Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12th World Congress for Hair Research. The presentation highlights THRIVE-AA1 study results evaluating Concert's investigational oral medicine deuruxolitinib (CTP-543) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The World Congress presentation includes new analyses from THRIVE‑AA1 showing the effect of deuruxolitinib on regrowth of scalp hai
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT. A webcast of the presentation may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay will be available on Concert's website for two weeks following the presentation. About Concert Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious
Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to be Presented at the World Congress for Hair Research Conference Call Scheduled Today at 8:30 a.m. ET; Registration Required to Join Live Call Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2022. "With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our way to meeting our goal of submitting the
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide a business update. To join the live call to ask questions, please register here. A dial in and unique PIN will be provided to join the call. An audio-only webcast of the call may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for three months. About Concert
35 Percent of Patients Treated With CTP-543 12 mg Twice-Daily Achieved At Least 90 Percent Scalp Hair Coverage (SALT Score ≤ 10) After 24 Weeks of Treatment Newly-Reported Results Show Significant Improvement in Eyebrow and Eyelash Regrowth in Patients Treated With Both Doses of CTP-543 Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA1. The presentation highlights THRIVE-AA1 study results evaluating Concert's oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The THRIVE-AA1 data are being pre
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022. The on-demand webcast of the presentation may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for two weeks following the presentation. About Concert Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a novel oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with CT
September is Alopecia Areata Awareness Month Alopecia Areata is a Serious Autoimmune Disorder with Limited Treatment Options In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this serious autoimmune disease. The effort will unite U.S. cities in observance of Alopecia Areata Awareness Month, which is recognized annually during September. The current illumination schedule follows below. Any updates or additions to the schedule will be posted here. If you plan to visit an illumination, we invite you to take a photo and tag your social media postings with the hashtag: #LightItUpBl
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale
Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to be Presented at the World Congress for Hair Research Conference Call Scheduled Today at 8:30 a.m. ET; Registration Required to Join Live Call Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2022. "With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our way to meeting our goal of submitting the
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide a business update. To join the live call to ask questions, please register here. A dial in and unique PIN will be provided to join the call. An audio-only webcast of the call may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for three months. About Concert
CTP-543 Positive Topline Results Reported in THRIVE-AA1 and THRIVE-AA2 Phase 3 Studies in Alopecia Areata CTP-543 Has the Potential to Address an Important Unmet Need for a Large, Underserved Patient Population Conference Call Scheduled Today at 8:30 a.m. ET; Online Registration Required to Access Dial in and PIN for Live Call to Ask Questions Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the second quarter of 2022. "We are very happy to have seen consistent efficacy and safety results across our two Phase 3 clinical trials of CTP-543 in alopecia areata. The positive results that we reported from THRIVE-AA1 in May and from THRIVE-AA2 earlier this week
New Online Registration Required for Live Call to Ask Questions Audio-Only Webcast Still Available on Concert's Website Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a business update. Please note that there is a new system to access the live call in order to ask questions. To join the live call, please register here. A dial in and unique PIN will be provided to join the call. An audio-only webcast of
Phase 3 Data Readout in Alopecia Areata Expected Second Quarter of 2022 Alopecia Areata Represents Significant Market Opportunity with Important Medical Need Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the first quarter of 2022. "We are at an exciting point in our progress with CTP-543, our drug candidate for alopecia areata, a serious autoimmune disorder with significant unmet medical need. Our pivotal trials, THRIVE-AA1 and THRIVE-AA2, have collectively enrolled over 1,200 patients in the U.S., Canada and Europe. We're grateful to the many individuals who chose to participate in our studies to advance
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its first quarter 2022 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International). A live webcast of the conference call may be accessed in the Investors section of the Company's website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled w
Two Phase 3 Registrational Clinical Trials Fully Enrolled for CTP-543 for the Treatment of Alopecia Areata CTP-543 THRIVE-AA1 Phase 3 Trial Topline Data Expected Second Quarter of 2022 CTP-543 THRIVE-AA2 Phase 3 Trial Topline Data Expected Third Quarter of 2022 Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2021. "Our team is extremely proud and motivated by our success in enrolling more than 1,200 patients in our THRIVE-AA Phase 3 program in line with our projected timelines. This represents a significant milestone for Concert as we focus on commercializing CTP-543 to help mee
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its fourth quarter 2021 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International). A live webcast of the conference call may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for three months.